Skip to main content
Top
Published in: Current Treatment Options in Oncology 5/2015

01-05-2015 | Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

Immunotherapy in Upper GI Malignancies

Authors: Adrian Murphy, MD, Ronan J. Kelly, MD

Published in: Current Treatment Options in Oncology | Issue 5/2015

Login to get access

Opinion statement

A comprehensive analysis of the interactions that can occur amongst three complex systems—the tumor cell, tissue microenvironment, and the immune response, is required if we are to realize the potential of immunotherapeutics in gastroesophageal cancer. For many years, epithelial cancers were believed to originate due to the transformation of tissue stem cells. Recently however, it has suggested that bone marrow-derived cells (BMDCs), which are frequently recruited to sites of tissue injury and inflammation, might also represent a potential source of malignancy. The link between infection, chronic inflammation, and cancer has long been recognized in gastric cancer with its close association with Helicobacter pylori as a class I carcinogen. The long-term consequences of recruiting pluripotent cells to areas of chronic inflammation which can result in altered cell signaling and differentiation needs to be defined, but this work provides a fascinating insight into the pivotal role played by the immune system in the development of upper GI tumors. Here, we discuss many of the immunotherapeutic strategies that have been assessed in gastroesophageal cancer in the last two decades. At the time of writing, the use of checkpoint inhibitors represents the most exciting approach and displays the greatest potential for widespread adoption in the clinic. Preliminary data suggest that programmed death ligand-1 (PD-L1) expression ranges from approximately 18 to 42 % in gastroesophageal cancer. Phase II and phase III clinical trials involving either single agent PD-1/PD-L1 inhibition or combined with CTLA-4 inhibitors are currently enrolling, and it is expected that checkpoint inhibition will become a new standard of care in the management of advanced disease in the near future.
Literature
1.
2.
go back to reference Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248(3):171–83.PubMedCrossRef Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248(3):171–83.PubMedCrossRef
3.•
go back to reference Fridman WH et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. This paper gives a comprehensive overview of the variety of immune cells that can have an impact on tumor progression and therefore affect survival rates of various cancers. It also provides an interesting overview of the role of immune cells in the tumor microenvironment.PubMedCrossRef Fridman WH et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. This paper gives a comprehensive overview of the variety of immune cells that can have an impact on tumor progression and therefore affect survival rates of various cancers. It also provides an interesting overview of the role of immune cells in the tumor microenvironment.PubMedCrossRef
4.
go back to reference Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735–40.PubMed Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735–40.PubMed
5.
go back to reference IARC Monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. In: Internatioanl Agency for Research on Cancer Moonograph 61, Lyon, France. 1994;177–240. IARC Monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. In: Internatioanl Agency for Research on Cancer Moonograph 61, Lyon, France. 1994;177–240.
6.
go back to reference Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology. 2005;128(6):1567–78.PubMedCrossRef Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology. 2005;128(6):1567–78.PubMedCrossRef
7.
go back to reference Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
8.
go back to reference Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
9.••
go back to reference Cancer Genome Atlas Research, N. Comprehensive molecular characteristics of gastric adenocarcinoma. Nature. 2014;513:202–9. This paper has greatly contributed to our knowledge of the molecular characterization of gastric cancer. It has provided four major subtypes with distinct molecular signatures many of which are immune-based. This has the potential to influence future selection for clinical trials.CrossRef Cancer Genome Atlas Research, N. Comprehensive molecular characteristics of gastric adenocarcinoma. Nature. 2014;513:202–9. This paper has greatly contributed to our knowledge of the molecular characterization of gastric cancer. It has provided four major subtypes with distinct molecular signatures many of which are immune-based. This has the potential to influence future selection for clinical trials.CrossRef
11.
go back to reference Bobryshev YV et al. Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett’s esophagus. J Gastrointest Surg. 2009;13(3):442–50.PubMedCrossRef Bobryshev YV et al. Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett’s esophagus. J Gastrointest Surg. 2009;13(3):442–50.PubMedCrossRef
12.
go back to reference Zingg U et al. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol. 2010;36(7):670–7.PubMedCrossRef Zingg U et al. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol. 2010;36(7):670–7.PubMedCrossRef
13.
go back to reference Wang F, ZS Lv, YK Fu. Nonsteroidal anti-inflammatory drugs and esophageal inflammation–Barrett’s esophagus–adenocarcinoma sequence: a meta-analysis. Dis Esophagus. 2011;24(5):318–24. Wang F, ZS Lv, YK Fu. Nonsteroidal anti-inflammatory drugs and esophageal inflammation–Barrett’s esophagus–adenocarcinoma sequence: a meta-analysis. Dis Esophagus. 2011;24(5):318–24.
14.
go back to reference Nguyen GH et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. Clin Cancer Res. 2010;16(23):5824–34.PubMedCentralPubMedCrossRef Nguyen GH et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. Clin Cancer Res. 2010;16(23):5824–34.PubMedCentralPubMedCrossRef
15.
go back to reference Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.PubMedCrossRef Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.PubMedCrossRef
16.
go back to reference Lundin BS et al. The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol. 2007;125(2):205–13.PubMedCrossRef Lundin BS et al. The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol. 2007;125(2):205–13.PubMedCrossRef
17.
go back to reference Enarsson K et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol. 2006;121(3):358–68.PubMedCrossRef Enarsson K et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol. 2006;121(3):358–68.PubMedCrossRef
18.
go back to reference Kao JY et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology. 2010;138(3):1046–54.PubMedCentralPubMedCrossRef Kao JY et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology. 2010;138(3):1046–54.PubMedCentralPubMedCrossRef
19.
go back to reference Szkaradkiewicz A et al. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol. 2010;2010:901564.PubMedCentralPubMedCrossRef Szkaradkiewicz A et al. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol. 2010;2010:901564.PubMedCentralPubMedCrossRef
20.
go back to reference El-Omar EM et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124(5):1193–201.PubMedCrossRef El-Omar EM et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124(5):1193–201.PubMedCrossRef
21.
go back to reference Figueiredo C et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002;94(22):1680–7.PubMedCrossRef Figueiredo C et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002;94(22):1680–7.PubMedCrossRef
22.
23.•
go back to reference Melero I et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(9):509–24. This paper gives a general oversight regarding the many types of vaccines used in anti-cancer therapy focusing on clinical trials in solid tumor types.PubMedCrossRef Melero I et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(9):509–24. This paper gives a general oversight regarding the many types of vaccines used in anti-cancer therapy focusing on clinical trials in solid tumor types.PubMedCrossRef
24.
go back to reference Ochiai T et al. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother. 1983;14(3):167–71.PubMedCrossRef Ochiai T et al. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother. 1983;14(3):167–71.PubMedCrossRef
25.
go back to reference Popiela T et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004;7(4):240–5.PubMedCrossRef Popiela T et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004;7(4):240–5.PubMedCrossRef
26.
go back to reference Sato Y et al. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother. 2004;27(5):394–7.PubMedCrossRef Sato Y et al. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother. 2004;27(5):394–7.PubMedCrossRef
27.
go back to reference Turcotte S et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 2013;191(5):2217–25.PubMedCentralPubMedCrossRef Turcotte S et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 2013;191(5):2217–25.PubMedCentralPubMedCrossRef
28.
go back to reference Kono K et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8(6):1767–71.PubMed Kono K et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8(6):1767–71.PubMed
29.
go back to reference Jiang J et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006;26(3B):2237–42.PubMed Jiang J et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006;26(3B):2237–42.PubMed
30.•
go back to reference Shi L et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61(12):2251–9. This paper showed that adjuvant immunotherapy (comprising autologous cytokine-induced killer cells) improved overall survival in patients with gastric cancer (particularly those with intestinal-type tumors).PubMedCentralPubMedCrossRef Shi L et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61(12):2251–9. This paper showed that adjuvant immunotherapy (comprising autologous cytokine-induced killer cells) improved overall survival in patients with gastric cancer (particularly those with intestinal-type tumors).PubMedCentralPubMedCrossRef
31.
go back to reference Fujiwara S et al. Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother. 2012;35(6):513–21.PubMedCrossRef Fujiwara S et al. Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother. 2012;35(6):513–21.PubMedCrossRef
32.
go back to reference Kono K et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8(11):3394–400.PubMed Kono K et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8(11):3394–400.PubMed
33.
go back to reference Sadanaga N et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001;7(8):2277–84.PubMed Sadanaga N et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001;7(8):2277–84.PubMed
34.
go back to reference Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res. 2012;32(8):3427–33.PubMed Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res. 2012;32(8):3427–33.PubMed
35.
go back to reference Ajani JA et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006;106(9):1908–16.PubMedCrossRef Ajani JA et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006;106(9):1908–16.PubMedCrossRef
36.
go back to reference Sato Y et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 2003;94(9):802–8.PubMedCrossRef Sato Y et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 2003;94(9):802–8.PubMedCrossRef
37.
go back to reference Iwahashi M et al. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. 2010;101(12):2510–7.PubMedCrossRef Iwahashi M et al. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. 2010;101(12):2510–7.PubMedCrossRef
38.
go back to reference Kono K et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012;10:141.PubMedCentralPubMedCrossRef Kono K et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012;10:141.PubMedCentralPubMedCrossRef
39.
go back to reference Kageyama S et al. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 2013;11:246.PubMedCentralPubMedCrossRef Kageyama S et al. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 2013;11:246.PubMedCentralPubMedCrossRef
40.
go back to reference Ohtsu A et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.PubMedCrossRef Ohtsu A et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.PubMedCrossRef
41.
go back to reference Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.PubMedCrossRef Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.PubMedCrossRef
42.
go back to reference Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.PubMedCrossRef Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.PubMedCrossRef
43.
go back to reference Masuzawa T et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41(4):1297–304.PubMed Masuzawa T et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41(4):1297–304.PubMed
44.
go back to reference Higashihara Y et al. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014;44(3):662–8.PubMedCentralPubMed Higashihara Y et al. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014;44(3):662–8.PubMedCentralPubMed
45.
go back to reference Jeung HC et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol. 2008;19(3):520–6.PubMedCrossRef Jeung HC et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol. 2008;19(3):520–6.PubMedCrossRef
46.
47.
go back to reference Butte MJ et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–22.PubMedCentralPubMedCrossRef Butte MJ et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–22.PubMedCentralPubMedCrossRef
48.
go back to reference Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23 Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23
49.
go back to reference Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65 Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65
50.
go back to reference Sun J et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 2007;69(1):19–27.PubMedCrossRef Sun J et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 2007;69(1):19–27.PubMedCrossRef
51.
go back to reference Muro K, Bang Y-J, Shankaran V, Geva R, Catenacci D, Gupta S, Eder J, Berger R, Gonzalez E, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford J, Cheng J, Koshiji M, Chung HC, Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 2015. 33:3; abstr 3. Muro K, Bang Y-J, Shankaran V, Geva R, Catenacci D, Gupta S, Eder J, Berger R, Gonzalez E, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford J, Cheng J, Koshiji M, Chung HC, Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 2015. 33:3; abstr 3.
50.••
go back to reference Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. This study aimed to determine the factors predicting response to the anti-PD-L1 antibody MPDL3280A. There is an association between clinical response and PD-L1 expression in pre-treatment tumor-infiltrating immune cells.PubMedCrossRef Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. This study aimed to determine the factors predicting response to the anti-PD-L1 antibody MPDL3280A. There is an association between clinical response and PD-L1 expression in pre-treatment tumor-infiltrating immune cells.PubMedCrossRef
51.•
go back to reference Robbins PF et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–52. Patients’ tumors were screened to identify candidate mutations which could predict clinical responses to autologous tumor-infiltrating lymphocytes. Mutated antigens were identified which were associated with objective tumor regression.PubMedCentralPubMedCrossRef Robbins PF et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–52. Patients’ tumors were screened to identify candidate mutations which could predict clinical responses to autologous tumor-infiltrating lymphocytes. Mutated antigens were identified which were associated with objective tumor regression.PubMedCentralPubMedCrossRef
Metadata
Title
Immunotherapy in Upper GI Malignancies
Authors
Adrian Murphy, MD
Ronan J. Kelly, MD
Publication date
01-05-2015
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 5/2015
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-015-0336-6

Other articles of this Issue 5/2015

Current Treatment Options in Oncology 5/2015 Go to the issue

Gynecologic Cancers (RJ Morgan, Section Editor)

Dose-Dense Approaches to Ovarian Cancer Treatment

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine